Signet Ring Cell Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: SGN002 MIFTS: 43	Signet Ring Cell Adenocarcinoma Categories: Cancer diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Signet Ring Cell Adenocarcinoma

MalaCards integrated aliases for Signet Ring Cell Adenocarcinoma:

Name: Signet Ring Cell Adenocarcinoma ¹¹ ¹⁴

Signet Ring Cell Carcinoma ¹¹ ¹⁶ ⁷⁵

Carcinoma, Signet Ring Cell ⁴³ ⁷¹

Carcinoma Signet Ring Cell ⁵³

Signet Ring Carcinoma ¹¹

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:3493

MeSH ⁴³ D018279

NCIt ⁴⁹ C3774

SNOMED-CT ⁶⁸ 189701002

EFO ¹⁶ EFO_0000698

UMLS ⁷¹ C0206696

Sources

Summaries for Signet Ring Cell Adenocarcinoma

Disease Ontology: ¹¹ An adenocarcinoma that derives from epithelial cells originating in glandular tissue, which have signet ring appearance.

MalaCards based summary: Signet Ring Cell Adenocarcinoma, also known as signet ring cell carcinoma, is related to bladder signet ring cell adenocarcinoma and bile duct signet ring cell carcinoma. An important gene associated with Signet Ring Cell Adenocarcinoma is KRT7 (Keratin 7), and among its related pathways/superpathways are Disease and TCR Signaling (Qiagen). The drugs Irinotecan and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include colon, lymph node and breast, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

Wikipedia: ⁷⁵ Signet ring cell carcinoma (SRCC) is a rare form of highly malignant adenocarcinoma that produces mucin.... more...

Sources

Related Diseases for Signet Ring Cell Adenocarcinoma

Diseases related to Signet Ring Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 704)

#	Related Disease	Score	Top Affiliating Genes
1	bladder signet ring cell adenocarcinoma	33.3	KRT7 CDX2
2	bile duct signet ring cell carcinoma	33.1	KRT7 KRT20
3	gastric signet ring cell adenocarcinoma	33.0	PIP KRT7 CDX2 CDH1
4	gallbladder signet ring cell adenocarcinoma	32.8	KRT7 KRT20 CDX2 CDH1
5	krukenberg carcinoma	32.7	KRT7 KRT20 CEACAM5 CDX2
6	rectum signet ring adenocarcinoma	32.7	MLH1 CEACAM5
7	pancreatic signet ring cell adenocarcinoma	32.0	TP53 MUC6 MUC5AC MLH1 KRAS HRAS
8	diffuse gastric and lobular breast cancer syndrome	31.7	TP53 PDPN MUC6 MLH1 KRAS ERBB2
9	bladder adenocarcinoma	31.2	TP53 KRT7 KRT20 CEACAM5 CDX2
10	diffuse gastric cancer	31.0	TP53 PDPN MLH1 KRAS ERBB2 CDH1
11	neuroendocrine carcinoma	30.9	KRT7 KRT20 CHGA CDH1
12	linitis plastica	30.9	PIP KRT7 KRT20 ERBB2 CEACAM5 CDX2
13	bile duct cysts	30.7	KRT7 KRAS HRAS CEACAM5
14	mucoepidermoid carcinoma	30.7	MUC5AC MUC2 KRT7 CDH1
15	ampulla of vater benign neoplasm	30.7	KRAS HRAS CHGA
16	small cell carcinoma	30.7	TP53 KRT7 KRT20 CHGA CEACAM5
17	appendiceal neoplasm	30.6	KRT7 KRAS HRAS CHGA CEACAM5 CDX2
18	cystitis cystica	30.6	KRT7 KRT20 CDX2
19	papillary carcinoma	30.6	KRT7 KRT20 ERBB2 CHGA CDH1
20	endodermal sinus tumor	30.6	KRT7 CHGA CEACAM5
21	exanthem	30.6	KRAS HRAS ERBB2
22	acute cholangitis	30.6	MUC6 MUC5AC CEACAM5
23	eyelid carcinoma	30.5	PIP KRT7 KRT20
24	intestinal obstruction	30.5	KRT7 KRT20 CEACAM5 CDX2
25	merkel cell carcinoma	30.5	KRT7 KRT20 CHGA
26	neuroendocrine tumor	30.5	KRT20 CHGA CDX2 CDH1
27	hepatoid adenocarcinoma	30.5	MUC6 KRT7 CEACAM5 CDX2
28	breast lobular carcinoma	30.5	TP53 PIP KRT7 ERBB2 CDH1
29	cystitis	30.5	TP53 KRT7 KRT20 CDH1
30	solid adenocarcinoma with mucin production	30.5	MUC6 MUC5AC KRT7 CHGA
31	vaginal cancer	30.5	TP53 KRT7 HRAS
32	glandular cystitis	30.5	TP53 KRT7 KRT20 CDX2
33	benign mesothelioma	30.4	PDPN KRT7 KRT20 CEACAM5
34	colon adenocarcinoma	30.4	TP53 MLH1 KRT20 KRAS HRAS CEACAM5
35	lymphangitis	30.4	PDPN KRT7 ERBB2 CEACAM5
36	appendix adenocarcinoma	30.4	TP53 KRT7 KRT20 KRAS HRAS CHGA
37	bladder urachal carcinoma	30.4	KRT7 KRAS HRAS CDX2
38	sweat gland cancer	30.4	TP53 PIP KRT7 KRT20 ERBB2 CEACAM5
39	esophagus adenocarcinoma	30.4	TP53 ERBB2 CDX2 CDH1
40	neurofibromatosis, type i	30.4	TP53 MLH1 KRAS HRAS
41	neurofibromatosis	30.4	TP53 MLH1 KRAS HRAS
42	adenosquamous carcinoma	30.3	MUC5AC KRT7 KRT20 KRAS HRAS CHGA
43	tubular adenocarcinoma	30.3	MUC6 MUC5AC MUC2 KRT7 KRT20 ERBB2
44	cholecystitis	30.3	TP53 MUC6 MUC5AC CDH1
45	paget disease, extramammary	30.3	PIP MUC5AC KRT7 KRT20 ERBB2 CEACAM5
46	thyroid gland follicular carcinoma	30.3	TP53 KRT7 HRAS CDH1
47	myoma	30.3	TP53 KRAS CEACAM5
48	papilloma	30.3	TP53 KRT7 KRT20 KRAS ERBB2 CDH1
49	endometrial adenocarcinoma	30.3	TP53 MLH1 KRT7 KRAS
50	thymus cancer	30.3	TP53 KRT7 HRAS ERBB2

Graphical network of the top 20 diseases related to Signet Ring Cell Adenocarcinoma:

Sources

Symptoms & Phenotypes for Signet Ring Cell Adenocarcinoma

GenomeRNAi Phenotypes related to Signet Ring Cell Adenocarcinoma according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Reduced mammosphere formation	GR00396-S	9.17	ARFIP2 CDH1 CHGA HRAS KRAS KRT7

MGI Mouse Phenotypes related to Signet Ring Cell Adenocarcinoma:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.21	CDH1 CDX2 CEACAM5 CHGA EPPIN ERBB2
2	growth/size/body region	MP:0005378	10.13	CDH1 CDX2 CEACAM5 CHGA EPPIN ERBB2
3	neoplasm	MP:0002006	10.1	CDH1 CDX2 CEACAM5 ERBB2 HRAS KRAS
4	endocrine/exocrine gland	MP:0005379	10.07	CDH1 CDX2 CEACAM5 CHGA EPPIN ERBB2
5	digestive/alimentary	MP:0005381	9.97	CDH1 CDX2 CEACAM5 EPPIN ERBB2 HRAS
6	cardiovascular system	MP:0005385	9.77	ARFIP2 CDH1 CDX2 CEACAM5 CHGA EPPIN
7	integument	MP:0010771	9.28	CDH1 EPPIN ERBB2 HRAS KRAS MLH1

Sources

Drugs & Therapeutics for Signet Ring Cell Adenocarcinoma

Drugs for Signet Ring Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Irinotecan

Approved, Investigational

Phase 3

97682-44-5, 100286-90-6

60838

Levoleucovorin

Approved, Experimental, Investigational

Phase 3

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Fluorouracil

Approved

Phase 3

51-21-8

3385

Bevacizumab

Approved, Investigational

Phase 3

216974-75-3

135329020

Capecitabine

Approved, Investigational

Phase 3

154361-50-9

60953

Oxaliplatin

Approved, Investigational

Phase 3

61825-94-3

43805 11947679 6857599

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 3

59-30-3

6037

Camptothecin

Experimental

Phase 3

7689-03-4

24360

Rivoceranib

Investigational

Phase 3

811803-05-1

11315474

topoisomerase I inhibitors

Phase 3

Formyltetrahydrofolates

Phase 3

Tetrahydrofolates

Phase 3

Antineoplastic Agents, Immunological

Phase 3

Immunoglobulins, Intravenous

Phase 3

Immunoglobulins

Phase 3

Antibodies, Monoclonal

Phase 3

Antibodies

Phase 3

Immunologic Factors

Phase 3

Cola

Phase 3

Vitamins

Phase 3

Folate

Phase 3

Vitamin B9

Phase 3

Trace Elements

Phase 3

Vitamin B Complex

Phase 3

Antidotes

Phase 3

Calcium, Dietary

Phase 3

Immunosuppressive Agents

Phase 3

Micronutrients

Phase 3

Protective Agents

Phase 3

Hormones

Phase 3

Immunoglobulin G

Phase 3

Angiogenesis Inhibitors

Phase 3

Hematinics

Phase 3

Endothelial Growth Factors

Phase 3

Mitogens

Phase 3

Antimetabolites

Phase 3

Protein Kinase Inhibitors

Phase 3

Calcium

Nutraceutical

Phase 3

7440-70-2

271

Nivolumab

Approved

Phase 2

946414-94-4

Talimogene laherparepvec

Approved, Experimental, Investigational

Phase 2

1187560-31-1

Turmeric

Approved, Experimental, Investigational

Phase 2

Curcumin

Approved, Investigational

Phase 2

458-37-7, 84765-67-3

969516

Immune Checkpoint Inhibitors

Phase 2

Antirheumatic Agents

Phase 2

Anti-Inflammatory Agents, Non-Steroidal

Phase 2

Turmeric extract

Phase 2

Anti-Inflammatory Agents

Phase 2

Analgesics, Non-Narcotic

Phase 2

Analgesics

Phase 2

Cetuximab

Approved

Phase 1

205923-56-4

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil and Leucovorin vs. 5-Fluorouracil and Leucovorin for Patients With Stage II or III Rectal Cancer Receiving Either Preoperative Radiation and 5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil	Completed	NCT00068692	Phase 3	Fluorouracil;Leucovorin Calcium;Oxaliplatin;Irinotecan
2	A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers	Active, not recruiting	NCT00217737	Phase 3	Fluorouracil;Leucovorin Calcium;Oxaliplatin
3	A Randomized, Multicenter, Controlled Study of XELOX (Oxaliplatin With Capecitabine) Combined With Apatinib Versus XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma With D2 Dissection.	Not yet recruiting	NCT03355612	Phase 3	Apatinib;XELOX
4	A Phase 2 Study of MK-2206 in Previously Treated Metastatic Colorectal Cancer Patients Enriched for PTEN Loss and PIK3CA Mutation	Completed	NCT01802320	Phase 2	Akt Inhibitor MK2206
5	A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors	Recruiting	NCT02978625	Phase 2
6	METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin	Recruiting	NCT05504252	Phase 2	Nivolumab;Oxaliplatin
7	A Randomized Double Blinded Study of Curcumin With Pre-operative Capecitabine and Radiation Therapy Followed by Surgery for Rectal Cancer	Terminated	NCT00745134	Phase 2	Capecitabine
8	Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer	Terminated	NCT01198535	Phase 1	Gamma-Secretase Inhibitor RO4929097
9	Has the Quota of Signet Ring Cells an Influence on Prognosis and Treatment Strategy in the Upper GI Tract Adenocarcinomas?	Completed	NCT01249859

Search NIH Clinical Center for Signet Ring Cell Adenocarcinoma

Cochrane evidence based reviews: carcinoma, signet ring cell

Sources

Genetic Tests for Signet Ring Cell Adenocarcinoma

Sources

Anatomical Context for Signet Ring Cell Adenocarcinoma

Organs/tissues related to Signet Ring Cell Adenocarcinoma:

MalaCards : Colon, Lymph Node, Breast, Prostate, Skin, Bone Marrow, Appendix

Sources

Publications for Signet Ring Cell Adenocarcinoma

Articles related to Signet Ring Cell Adenocarcinoma:

(show top 50) (show all 2183)

#	Title	Authors	PMID	Year
1	Chromogranin A expression correlates with tumour cell type and prognosis in signet ring cell carcinoma of the stomach. ⁵³ ⁶²	Fujiyoshi Y...Eimoto T	18269581	2008
2	Distinct expression patterns of E-cadherin and beta-catenin in signet ring cell carcinoma components of primary pulmonary adenocarcinoma. ⁵³ ⁶²	Moon KC...Chung DH	16948518	2006
3	Primary cutaneous signet ring cell carcinoma expressing cytokeratin 20 immunoreactivity. ⁵³ ⁶²	Kiyohara T...Ansai S	16488312	2006
4	Dynamic alteration of the E-cadherin/catenin complex during cell differentiation and invasion of undifferentiated-type gastric carcinomas. ⁵³ ⁶²	Nakamura E...Hattori T	15682444	2005
5	Molecular characteristics of eight gastric cancer cell lines established in Japan. ⁵³ ⁶²	Yokozaki H	11107048	2000
6	The role of cytokeratins 20 and 7 and estrogen receptor analysis in separation of metastatic lobular carcinoma of the breast and metastatic signet ring cell carcinoma of the gastrointestinal tract. ⁵³ ⁶²	Tot T	11028811	2000
7	Gastric metastasis of mammary signet ring cell carcinoma--a differential diagnosis with primary gastric signet ring cell carcinoma. ⁵³ ⁶²	Yim H...Park HB	9250925	1997
8	A case of small cell carcinoma of the stomach. ⁵³ ⁶²	Matsui T...Nakao A	9058136	1997
9	E-cadherin gene mutations in signet ring cell carcinoma of the stomach. ⁵³ ⁶²	Muta H...Hirohashi S	8797891	1996
10	Marked elevation of plasma carcinoembryonic antigen and stomach carcinoma. ⁵³ ⁶²	Horie Y...Kawasaki H	8640661	1996
11	Breast metastasis of signet ring cell carcinoma from the colon: a case report. ⁶²	Wang X...Lu Y	36451153	2022
12	Therapeutic plasma exchange in gastric signet ring cell carcinoma presenting as microangiopathic hemolytic anemia: A rare case report. ⁶²	Candar O...Aras I	36125111	2022
13	Bilateral ovarian metastasis after laparoscopic right hemicolectomy for signet-ring cell carcinoma. ⁶²	Wu CY...Ye K	35780022	2022
14	Exceptional Variant with Distant Cutaneous Metastasis as the First Clinical Sign in Gastric Signet-Ring Carcinoma. ⁶²	Bulut E...Gokyer A	34786642	2022
15	Peritoneal metastatic mixed adenoneuroendocrine carcinoma treated with cytoreduction surgery and hyperthermic intraperitoneal chemotherapy: a case report. ⁶²	Lee S...Park DG	36404497	2022
16	Pleural metastasis from pulmonary primary signet-ring squamous cell carcinoma. Case report and literature review. ⁶²	Torres-Rivas HE...Fernandez Fernandez LM	36318823	2022
17	Epidemiology and prognostic analysis of patients with pancreatic signet ring cell carcinoma: a population-based study. ⁶²	Nie D...Chen Y	36384527	2022
18	The therapeutic efficacy of radical prostatectomy and external beam radiation therapy in patients with different pathological patterns of prostate cancer. ⁶²	Zhao J...Zeng H	36376185	2022
19	Survival Outcomes and Clinicopathological Features in Inflammatory Bowel Disease-associated Colorectal Cancer: A Systematic Review and Meta-analysis. ⁶²	Lu C...Kuhn F	34913897	2022
20	Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability‒High Colon Cancer. ⁶²	Hyung J...Kim SY	35038827	2022
21	Clinical features and prognostic factors of esophageal signet ring cell carcinoma: construction and validation of a model based on the SEER database. ⁶²	Xie R...Li L	36388034	2022
22	Gastric Cancer After Helicobacter pylori Eradication for Nodular Gastritis in an Adolescent. ⁶²	Okmaura T...Nagaya T	36381762	2022
23	Clinicopathological Characteristics of Advanced Epstein-Barr Virus-associated Gastric Cancer Highlighting Aberrant p53 Expression. ⁶²	Jang H...Kim M	36191967	2022
24	Clinicopathological and molecular characterization of early gastric adenocarcinoma in Helicobacter pylori-uninfected patients: emphasis on differentiated gastric adenocarcinoma. ⁶²	Akazawa Y...Nagahara A	35939123	2022
25	Genomically stable gastric cancer characterized by hypomethylation in Wnt signal cascade. ⁶²	Tanioka H...Nagasaka T	36244328	2022
26	Superficial nonampullary duodenal epithelial tumor: a rare case with signet-ring cell carcinoma component diagnosed by magnifying endoscopy. ⁶²	Muramoto T...Minato Y	36216257	2022
27	Signet Ring Cell Carcinoma at the Ampulla of Vater: A Very Rare Diagnosis. ⁶²	Dawande PP...Bankar NJ	36407266	2022
28	Clinicopathological characteristics and prognosis of gastric signet ring cell carcinoma. ⁶²	Tian HK...Li H	36312481	2022
29	Primary signet ring cell carcinoma of the appendix: An interesting case. ⁶²	Wang F...Tang G	35595079	2022
30	Pathological Nodal Staging Score for Gastric Signet Ring Cell Carcinoma: A Clinical Tool of Adequate Nodal Staging. ⁶²	Yu C...Li Y	36291978	2022
31	Colorectal signet-ring cell carcinoma treated with FOLFOX plus panitumumab. ⁶²	Matsushima S...Kobayashi K	36169041	2022
32	Primary signet-ring cell carcinoma of the cecum: A rare case report. ⁶²	Anas D...Mohammed B	35973320	2022
33	Pathological and oncological outcomes of pylorus-preserving versus conventional distal gastrectomy in early gastric cancer: a systematic review and meta-analysis. ⁶²	Hou S...Ye Y	36153587	2022
34	Glycan expression profile of signet ring cell gastric cancer cells and potential applicability of rBC2LCN-targeted lectin drug conjugate therapy. ⁶²	Yang Y...Oda T	35715659	2022
35	Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma model. ⁶²	Yamaguchi K...Baba E	35661943	2022
36	Superiority of [68Ga]Ga-FAPI-04/[18F]FAPI-42 PET/CT to [18F]FDG PET/CT in delineating the primary tumor and peritoneal metastasis in initial gastric cancer. ⁶²	Fu L...Zhou W	35380229	2022
37	Microangiopathic Hemolytic Anemia Is a Late and Fatal Complication of Gastric Signet Ring Cell Carcinoma: A Systematic Review and Case-Control Study. ⁶²	Lam R...Li DK	35589098	2022
38	Mucinous Proliferations of the Uterine Corpus: Comprehensive Appraisal of an Evolving Spectrum of Neoplasms. ⁶²	Fadare O	35499137	2022
39	Immunohistochemical analysis of PD-L1 and tumor-infiltrating immune cells expression in the tumor microenvironment of primary signet ring cell carcinoma of the prostate. ⁶²	Teng QL...Liu ZY	35042311	2022
40	Risk factors for metachronous peritoneal carcinomatosis after radical resection for patients with nonmetastatic pT3-4 colon cancer. ⁶²	Mo TW...He XW	35661159	2022
41	Colonic infiltration of chronic lymphocytic leukemia with Hodgkin Reed Sternberg-like cells. ⁶²	Nova-Camacho LM...Riego Repullo V	35297262	2022
42	Signet-ring cell carcinoma of the appendix with ganglioneuromatosis: a case report. ⁶²	Sato A...Okazumi S	35927360	2022
43	Clinical value and influencing factors of establishing stomach cancer organoids by endoscopic biopsy. ⁶²	Li J...Zhan X	35987927	2022
44	Genomic analysis of an aggressive case with metastatic intrahepatic mucinous cholangiocarcinoma. ⁶²	Masaki Y...Nakase H	35699889	2022
45	Comparison of [68Ga]Ga-FAPI and [18F]FDG uptake in patients with gastric signet-ring-cell carcinoma: a multicenter retrospective study. ⁶²	Chen H...Sun L	35976396	2022
46	Nerve invasion as an independent predictor of poor prognosis in gastric cancer after curative resection. ⁶²	Li C...Xiao H	35984131	2022
47	Treatment outcomes of patients with involved resection margin after rectal cancer surgery: A nationwide population-based cohort study in South Korea. ⁶²	Bong JW...Min BW	34310853	2022
48	Surveillance of Russell body inflammation of the digestive tract: a case report and review of literature. ⁶²	Luo S...Wang J	36002890	2022
49	Trends, clinicopathological features, surgical treatment patterns and prognoses of early-onset versus late-onset colorectal cancer: A retrospective cohort study on 34067 patients managed from 2000 to 2021 in a Chinese tertiary center. ⁶²	Gao XH...Zhang W	35850466	2022
50	Endoscopic submucosal dissection for early signet ring cell gastric cancer: A systematic review and meta-analysis. ⁶²	Weng CY...Lv B	36051146	2022

Sources

Genes for Signet Ring Cell Adenocarcinoma

Genes related to Signet Ring Cell Adenocarcinoma (0 elite genes):

(show all 27)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	KRT7	Keratin 7	Protein Coding	15.35	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11028811
2	CDH1	Cadherin 1	Protein Coding	14.59	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16948518 15682444 8797891 (more) 19432899 11107048
3	KRT20	Keratin 20	Protein Coding	14.58	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11028811 16488312
4	PIP	Prolactin Induced Protein	Protein Coding	13.52	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9250925
5	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	11.32	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8640661
6	CHGA	Chromogranin A	Protein Coding	9.77	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18269581 16344325 9058136
7	MUC2	Mucin 2, Oligomeric Mucus/Gel-Forming	Protein Coding	9.18	Novoseek inferred ⁵³	19102008
8	CDX2	Caudal Type Homeobox 2	Protein Coding	7.55	DISEASES inferred ¹⁴
9	ARFIP2	ADP Ribosylation Factor Interacting Protein 2	Protein Coding	7.13	DISEASES inferred ¹⁴
10	MUC6	Mucin 6, Oligomeric Mucus/Gel-Forming	Protein Coding	7.11	DISEASES inferred ¹⁴
11	MUC5AC	Mucin 5AC, Oligomeric Mucus/Gel-Forming	Protein Coding	7.09	DISEASES inferred ¹⁴
12	EPPIN	Epididymal Peptidase Inhibitor	Protein Coding	6.87	DISEASES inferred ¹⁴ ¹⁴
13	TMEM207	Transmembrane Protein 207	Protein Coding	6.82	DISEASES inferred ¹⁴
14	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	6.55	DISEASES inferred ¹⁴
15	MLH1	MutL Homolog 1	Protein Coding	6.53	DISEASES inferred ¹⁴
16	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	6.53	DISEASES inferred ¹⁴
17	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	6.47	DISEASES inferred ¹⁴
18	PDPN	Podoplanin	Protein Coding	6.43	DISEASES inferred ¹⁴
19	TP53	Tumor Protein P53	Protein Coding	6.42	DISEASES inferred ¹⁴
20	SRC	SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase	Protein Coding	6.39	DISEASES inferred ¹⁴
21	PMS2	PMS1 Homolog 2, Mismatch Repair System Component	Protein Coding	6.32	DISEASES inferred ¹⁴
22	MSH2	MutS Homolog 2	Protein Coding	6.31	DISEASES inferred ¹⁴
23	MSH6	MutS Homolog 6	Protein Coding	6.28	DISEASES inferred ¹⁴
24	CLDN18	Claudin 18	Protein Coding	6.26	DISEASES inferred ¹⁴
25	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	6.23	DISEASES inferred ¹⁴
26	CTNNB1	Catenin Beta 1	Protein Coding	5.99	DISEASES inferred ¹⁴
27	SERPINA3	Serpin Family A Member 3	Protein Coding	5.91	DISEASES inferred ¹⁴ ¹⁴

Sources

Variations for Signet Ring Cell Adenocarcinoma

Sources

Expression for Signet Ring Cell Adenocarcinoma

Search GEO for disease gene expression data for Signet Ring Cell Adenocarcinoma.

Sources

Pathways for Signet Ring Cell Adenocarcinoma

Pathways related to Signet Ring Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 40)

#	Super pathways	Score	Top Affiliating Genes
1	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.76	TP53 SRC MUC6 MUC5AC MLH1 KRAS
2	TCR Signaling (Qiagen) ⁶⁴ Show member pathways Fc-EpsilonRI Pathway ⁶⁴ ITK and TCR Signaling ⁶⁴ PDGF Pathway ⁶⁴ PKC-Theta Pathway ⁶⁴	12.85	TP53 SRC MLH1 KRAS HRAS ARFIP2
3	fMLP Pathway ⁶⁴ Show member pathways CXCR4 Pathway ⁶⁴ Huntington's Disease Pathway ⁶⁴ Internalin Pathway ⁶⁴ Signal transduction Activation of PKC via G-Protein coupled receptor ²²	12.71	TP53 KRAS HRAS CDH1 ARFIP2
4	IL-1 Family Signaling Pathways ⁶⁵ Show member pathways IL1 signaling pathway ⁶⁷ Immune response IL-1 signaling pathway ²² Interleukin-1 (IL-1) structural pathway ⁷⁴ Interleukin-33 signaling ⁶⁶ Interleukin-36 pathway ⁶⁶ Mucin expression in CF via TLRs, EGFR signaling pathways ²² Pathogen or Damage-activated C-Type Lectin Receptor Signaling Pathways ⁶⁵	12.55	SRC MUC5AC MUC2 KRAS HRAS
5	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.51	ERBB2 HRAS KRAS SRC TP53
6	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.4	TP53 KRAS HRAS ERBB2
7	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.38	TP53 KRAS HRAS ERBB2
8	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.34	TP53 SRC HRAS ERBB2 CDH1
9	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.32	KRAS HRAS ERBB2 CDH1 ARFIP2
10	CLEC7A (Dectin-1) signaling ⁶⁶ Show member pathways Alternative NF-kappaB pathway ⁶¹ CLEC7A/inflammasome pathway ⁶⁶ C-type lectin receptors (CLRs) ⁶⁶	12.3	SRC MUC6 MUC5AC KRAS HRAS
11	Cell surface interactions at the vascular wall ⁶⁶ Show member pathways Fibronectin matrix formation ⁶⁶ PECAM1 interactions ⁶⁶ Tie2 Signaling ⁶⁶	12.16	CEACAM5 HRAS KRAS SRC
12	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.12	ERBB2 HRAS KRAS SRC TP53
13	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.12	TP53 SRC KRAS HRAS ERBB2 CDH1
14	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.12	TP53 SRC MLH1 KRAS HRAS ERBB2
15	Epithelial to mesenchymal transition in colorectal cancer ⁷⁴	12.11	TP53 KRAS HRAS CDH1
16	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ⁶¹ Nuclear signaling by ERBB4 ⁶⁶	11.99	SRC KRAS HRAS ERBB2
17	Colorectal Cancer Metastasis ⁶⁴	11.98	TP53 SRC MLH1 KRAS CDH1
18	Signaling by ERBB2 ⁶⁶ Show member pathways Downregulation of ERBB2 signaling ⁶⁶ Downregulation of ERBB2:ERBB3 signaling ⁶⁶ ERBB2 Activates PTK6 Signaling ⁶⁶ ERBB2 Regulates Cell Motility ⁶⁶ GRB7 events in ERBB2 signaling ⁶⁶	11.96	SRC KRAS HRAS ERBB2
19	G12-G13 in Cellular Signaling ⁶⁴	11.94	SRC KRAS HRAS CDH1
20	Signaling by SCF-KIT ⁶⁶ Show member pathways Regulation of KIT signaling ⁶⁶ Signaling by KIT in disease ⁶⁶ Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants ⁶⁶	11.85	SRC KRAS HRAS
21	Signaling by EGFR ⁶⁶ Show member pathways EGFR downregulation ⁶⁶ GAB1 signalosome ⁶⁶	11.85	SRC KRAS HRAS
22	DNA damage response (only ATM dependent) ⁷⁴	11.79	TP53 KRAS HRAS ERBB2
23	Signaling by PDGF ⁶⁶ Show member pathways Downstream signal transduction ⁶⁶	11.78	SRC KRAS HRAS
24	Thyroid hormones production and peripheral downstream signaling effects ⁷⁴	11.75	TP53 SRC HRAS
25	mTOR Pathway ⁷⁰ Show member pathways TGF-beta Pathway ⁷⁰	11.72	TP53 KRAS HRAS
26	MAPK Signaling: Oxidative Stress ⁶⁵	11.72	TP53 SRC KRAS
27	Gastrin signaling pathway ⁷⁴	11.7	CDH1 CHGA HRAS KRAS SRC
28	Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ⁶¹	11.67	CDH1 HRAS SRC
29	Pathways affected in adenoid cystic carcinoma ⁷⁴	11.6	TP53 HRAS ERBB2
30	Cytoskeleton remodeling Role of PDGFs in cell migration ²² Show member pathways Osteoblast signaling ⁷⁴ PDGF pathway ⁷⁴ PDGF receptor signaling network ⁶¹	11.59	SRC HRAS ARFIP2
31	Head and neck squamous cell carcinoma ⁷⁴	11.57	TP53 KRAS HRAS ERBB2
32	Posttranslational regulation of adherens junction stability and dissassembly ⁶¹	11.47	SRC HRAS CDH1
33	Agrin Interactions at Neuromuscular Junction ⁶⁴	11.38	SRC KRAS HRAS ERBB2
34	a6b1 and a6b4 Integrin signaling ⁶¹	11.32	HRAS ERBB2 CDH1
35	Extracellular vesicle-mediated signaling in recipient cells ⁷⁴	11.15	KRAS HRAS ERBB2
36	MNAR-PELP1 and Estrogen Receptor Interaction ⁶⁴	10.99	HRAS KRAS SRC
37	VEGFR2 mediated cell proliferation ⁶⁶	10.93	SRC KRAS HRAS
38	TNF-alpha signaling pathway ⁷⁴ Show member pathways RAS GTPase cycle mutants ⁶⁶ Signaling by RAS GAP mutants ⁶⁶ Signaling by RAS GTPase mutants ⁶⁶	10.75	KRAS HRAS
39	Bladder cancer ⁷⁴	10.7	TP53 SRC KRAS HRAS ERBB2 CDH1
40	Mammary gland development pathway - Involution (Stage 4 of 4) ⁷⁴	10.65	TP53 CDH1